Levetiracetam

Producers shown on SFDA

(Record date:30/08/2021）

Producers shown on EP

(Quoted from EP website；record date:30/08/2021）

Producer:Venturepharm (Hainan) Co., Ltd.,is a group providing outsourced production service management for global pharmaceutical enterprises, which is authorized and managed by venturepharm Group Inc.

With 7 advanced API and preparation production bases in Asia, the company provides comprehensive production outsourcing services for global pharmaceutical enterprises. Customers can obtain professional support and services from the early stage of product development to large-scale production. All production bases of vante have passed GMP certification, and two API production bases have passed FDA certification.

Staff size:100-199 persons

Registered capital:RMB 194 million 870 thousand and 600

Producer:Chongqing Shenghuaxi Pharmaceutical Co., Ltd. was established in 1998 and officially restructured into a joint stock limited company in 2010; At present, the company has more than 900 employees. After more than ten years of development, it has been established   Jingjing is a high-tech API and pharmaceutical preparation enterprise integrating R & D, production and sales.

Taking new drug R & D as the core competitiveness of the enterprise, the company has built a large-scale scientific research system, with more than 200 full-time scientific and technological developers; The company invests more than 12% of its sales revenue into new drug research and development every year. The company has three production bases, with more than ten fully sterile API and non sterile API production workshops, fine, drying and charter workshops, as well as a number of pharmaceutical preparation workshops; It has an annual production capacity of more than one billion yuan for APIs and pharmaceutical preparations.

Staff size:About 800 persons

Registered capital:RMB 66 million

Producer:Second Pharma Co., Ltd., was established in 2003, covering an area of 200 mu. It is the relocation of the API business of Beijing SECCO Pharmaceutical (formerly Beijing No. 2 pharmaceutical factory, subordinate to Beijing Pharmaceutical Group) from Beijing. It is jointly invested and established by SECCO pharmaceutical and Zhejiang XinHeCheng.

The company is recognized as a national high-tech enterprise, has established a perfect quality management system, is equipped with advanced instruments and equipment, and has passed the cGMP certification inspection of FDA and the PQ certification of who for many times. The company strictly performs its social responsibilities, attaches great importance to safety, environmental protection and labor employment, and has passed cleaner production audit, safety standardization acceptance, ISO14001 environmental management system certification and OHSAS18001 occupational health and safety management system certification.

Staff size:300-399 persons
Registered capital:RMB 80.12 million

Producer:Renhe Yikang Pharmaceutical Co., Ltd., a subsidiary of Renhe Yikang group, was established in 2016, with API workshop, oral solution workshop, small volume injection workshop and oral solid preparation workshop. Oral solution workshop and small volume injection workshop have obtained GMP certificate.

Staff size:300-399 persons
Registered capital:RMB 20 million

Producer:Shangyu Jingxin Pharmaceutical Co., Ltd. is a wholly-owned subsidiary of Zhejiang Jingxin Pharmaceutical Co., Ltd. Zhejiang Jingxin Pharmaceutical Co., Ltd. is one of the top 100 pharmaceutical enterprises in China and a listed pharmaceutical company. The company is located in the West Zone of Shangyu Industrial Park, Hangzhou Bay, Zhejiang Province. Its products are mainly the production of APIs. It is one of the largest production bases of quinolone APIs in China“ Cyclopropyl hydrochloride and levofloxacin hydrochloride occupy a large market share in China. API products sell well in Southeast Asia, South Asia, Latin America, Europe and other international markets.

The company has fully passed the national GMP certification, ISO14001 certification, simvastatin has obtained cos certificate, ciprofloxacin hydrochloride has obtained cos certificate, French GMP certificate, EU GMP certificate and KFDA registration certificate.

Staff size:500-599 persons

Registered capital:RMB 150 million

Producer:Shenzhen Salubris Pharmaceuticals Co., Ltd., established in 1998 and listed on Shenzhen Stock Exchange in 2009, is a comprehensive pharmaceutical listed company integrating pharmaceutical product R & D, production and sales. The company accurately distributes the global industrial chain, covering more than 30 countries and regions such as China, the United States, Germany, France and Japan. All products and production workshops of the company have passed the domestic GMP certification, Daya Bay production base has passed the EU GMP certification, and the key product Taijia has obtained the listing license of 12 EU countries. All kinds of products enjoy a good reputation in the industry.
Staff size:About 3500 persons

Registered capital:RMB 1 billion 115 million

Producer:Zhuhai United Laboratories Co., Ltd. is a subsidiary of The United Laboratories International Holdings Limited (United Lab). United Lab now has 11 major series of preparation products, more than 60 varieties, more than 120 product specifications, and nearly 50 varieties of 5 major series of API and intermediate products. All workshops of UL have passed the new version of GMP certification in China, and many products have successively obtained EU GMP certification and US FDA certification. With advanced enzymatic production technology, UL has become the first enterprise in China to obtain the EU CEP certificate of enzymatic amoxicillin, and a number of scientific and technological achievements have obtained national patents.

United Labowns advanced production equipment and adequate production capacity. Every year, it can produce 1.8 billion capsules, 1 billion tablets, 134 million sachets of granules, 86 million sachets of suspension, 20 million vials of oral solution, 117 million vials of powder injections, 37.8 million tubes of ointments, 28 million vials of lyophilized powder for injection, 24 million tubes of eye drops and about 300 million tubes of insulin preparation.

Staff size:2000-2999 persons

Registered capital:RMB 1 billion 678 million 396 thousand